A single injection that turns the body into an antibody factory has provided a full year of protection against an HIV-like virus.
April 25, 2026
Original Paper
Durable protection against SIV challenge by adeno-associated virus delivery of Env-specific antibodies
bioRxiv · 10.64898/2026.04.20.719478
AI-generated illustration
The Takeaway
Traditional vaccines for HIV and its relative SIV have failed for decades because the viruses evolve too quickly for the immune system to keep up. This new approach uses a viral vector to deliver the genetic instructions for producing powerful antibodies directly into the host cells. In a study on monkeys, 14 out of 16 animals resisted multiple attempts to infect them over the course of a year. This bypasses the need for the body to learn how to fight the virus, as it is already making the cure. This permanent antibody production could be the breakthrough needed to finally end the HIV epidemic. We are effectively engineering immunity instead of teaching it.
From the abstract
Conventional vaccines have so far failed to elicit the types of antibodies needed for protection against HIV. As an alternative, we evaluated adeno-associated virus (AAV) delivery of rhesus macaque antibodies to the SIV envelope glycoprotein for protection against SIV challenge. AAV vectors encoding a broadly neutralizing antibody (bnAb) and an antibody that only mediates antibody-dependent cellular cytotoxicity (ADCC) were administered individually or together to separate groups of rhesus macaq